A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of intravenous (iv) or subcutaneous (sc)
Mircera, administered with pre-filled syringes, as maintenance treatment for renal anemia in
chronic kidney disease patients on dialysis who were previously receiving iv or sc epoetin.
The anticipated time on study treatment is 3-12 months and the target sample size is 100-500
individuals.